Education
About Us
Working with TipRanks
Follow Us
Entrada Therapeutics Inc (TRDA)
NASDAQ:TRDA
Total Valuation
Entrada Therapeutics Inc has a market cap or net worth of $444.86M. The enterprise value is $441.34M.
Market Cap$444.86M
Enterprise Value$441.34M
Share Statistics
Entrada Therapeutics Inc has 38,284,313 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding38,284,313
Owned by Insiders36.14%
Owned by Institutions0.72%
Financial Efficiency
Entrada Therapeutics Inc’s return on equity (ROE) is -0.47 and return on invested capital (ROIC) is -43.69%.
Return on Equity (ROE)-0.47
Return on Assets (ROA)-0.38
Return on Invested Capital (ROIC)-43.69%
Return on Capital Employed (ROCE)-0.44
Revenue Per Employee138.91K
Profits Per Employee-785.52K
Employee Count183
Asset Turnover0.07
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Entrada Therapeutics Inc is ―. Entrada Therapeutics Inc’s PEG ratio is 0.00996.
PE Ratio―
PS Ratio16.73
PB Ratio1.39
Price to Fair Value1.39
Price to FCF-3.28
Price to Operating Cash Flow-4.05
PEG Ratio0.00996
Income Statement
In the last 12 months, Entrada Therapeutics Inc had revenue of 25.42M and earned -143.75M in profits. Earnings per share was -3.47.
Revenue25.42M
Gross Profit21.32M
Operating Income-156.00M
Pretax Income-142.83M
Net Income-143.75M
EBITDA-142.40M
Earnings Per Share (EPS)-3.47
Cash Flow
In the last 12 months, operating cash flow was -128.51M and capital expenditures -1.04M, giving a free cash flow of -129.55M billion.
Operating Cash Flow-128.51M
Free Cash Flow-129.55M
Free Cash Flow per Share-3.38
Dividends & Yields
Entrada Therapeutics Inc pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.53
52-Week Price Change19.81%
50-Day Moving Average11.00
200-Day Moving Average8.06
Relative Strength Index (RSI)52.02
Average Volume (3m)219.52K
Important Dates
Entrada Therapeutics Inc upcoming earnings date is May 7, 2026, Before Open (Confirmed).
Last Earnings DateFeb 26, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Entrada Therapeutics Inc as a current ratio of 12.53, with Debt / Equity ratio of 16.64%
Current Ratio12.53
Quick Ratio12.53
Debt to Market Cap0.12
Net Debt to EBITDA0.28
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Entrada Therapeutics Inc has paid 924.00K in taxes.
Income Tax924.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Entrada Therapeutics Inc EV to EBITDA ratio is -2.71, with an EV/FCF ratio of -2.98.
EV to Sales15.18
EV to EBITDA-2.71
EV to Free Cash Flow-2.98
EV to Operating Cash Flow-3.00
Balance Sheet
Entrada Therapeutics Inc has $295.70M in cash and marketable securities with $50.93M in debt, giving a net cash position of $244.77M billion.
Cash & Marketable Securities$295.70M
Total Debt$50.93M
Net Cash$244.77M
Net Cash Per Share$6.39
Tangible Book Value Per Share$7.40
Margins
Gross margin is -54.39%, with operating margin of -613.66%, and net profit margin of -565.48%.
Gross Margin-54.39%
Operating Margin-613.66%
Pretax Margin-561.84%
Net Profit Margin-565.48%
EBITDA Margin-560.17%
EBIT Margin-561.84%
Analyst Forecast
The average price target for Entrada Therapeutics Inc is $20.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$20.00
Price Target Upside72.12% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast-71.42%
EPS Growth Forecast-248.91%